Randomized, Contralateral Eye Study to Evaluate the Safety Efficacy of anti-glaucoma treatment for prevention of regression after Myopic LASIK

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR-TRC-14004839

Enrollment

Unknown

Registered

2014-09-21

Start date

2014-07-09

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Refractive error

Interventions

Two groups:One eye of each patient would receive preservative free timolol 0.5% eye drops twice daily in one randomly chosen eye. Another one use placebo. Treatment would be started at 1 week after su

Eligibility

Sex/Gender

All

Age

21 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Patients with myopia or myopic astigmatism aged 21 years or more; 2. Anisometropia < 1 diopter.

Exclusion criteria

Exclusion criteria: 1. Patients aged < 21 years; 2. Patients in which the target refraction is not emmetropia; 3. Patients with ocular inflammation, diabetes mellitus, connective tissue disorders; 4. Patients who have used retinoid acid or equivalent in the past 6 months; 5. Patients with known cardiac disease or bronchial asthma.

Design outcomes

Secondary

Measure	Time frame
1. Change in corneal thickness on corneal topography;2. Change in corneal thickness on corneal topography;3. Adverse effects associated with the treatment;	—

Primary

Measure	Time frame
1. Spherical equivalent;2. Uncorrected visual acuity (UCVA);	—

Countries

China

Contacts

Public ContactDr. Jhanji, Vishal

The Chinese University of Hong Kong

vishaljhanji@cuhk.edu.hk+83943580752

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026